Short Interest in Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) Expands By 37.2%

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) saw a significant growth in short interest in February. As of February 28th, there was short interest totalling 26,200 shares, a growth of 37.2% from the February 13th total of 19,100 shares. Based on an average trading volume of 53,400 shares, the short-interest ratio is currently 0.5 days.

Wall Street Analyst Weigh In

Separately, Raymond James restated a “strong-buy” rating on shares of Medexus Pharmaceuticals in a research note on Monday, February 3rd.

Medexus Pharmaceuticals Stock Performance

OTCMKTS MEDXF traded down $0.02 during trading hours on Tuesday, hitting $1.77. The company had a trading volume of 3,575 shares, compared to its average volume of 39,077. Medexus Pharmaceuticals has a 1-year low of $1.08 and a 1-year high of $3.88. The business has a 50 day moving average of $2.37 and a 200-day moving average of $2.06.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.